Bribery, corruption and misconduct risks are particularly high in the life sciences space – pharmaceuticals, medical devices, medical technologies and medical advisory – given the intersection between emerging markets, government officials, reliance on third parties, rising medical costs, growing populations, wage differentials and the necessity of the services. The risks are noticeably pronounced in China, Vietnam and Indonesia: three Asian countries where rapid economic growth, significant healthcare spending and complex regulatory environments have created fertile ground for compliance challenges in this sector. In this guest article, Hogan Lovells attorneys based in Asia undertake a cross-jurisdictional review of the healthcare sector for three of Asia’s largest economies; identify how, where and why corruption and compliance risks may manifest; and recommend risk mitigation steps for companies. See “Internal Investigations in the Life Sciences Industry” (Jul. 8, 2020).